| Field Name |
Data Description |
| Test Name |
Disopyramide Level |
| Code |
Disopyramide Level. |
|
CPT Code |
80299 |
| Last Modified |
4/9/2018 1:16:00 PM |
| Test Name |
Disopyramide. |
| Synonyms |
Rythmodace, Disopyramide, Norpace, TDM, |
| Patient Preparation |
|
| Spec. Requirements |
Blood |
| Tube |
Red, Lavender (EDTA), Drk Green (Heparin) |
| Collection Volume |
4.0 mL Red or Drk Green, or 2.0 mL Lav |
| Storage |
Ambient, Frozen, Refrigerated 14 days |
| Routine TAT |
3-5 |
| STAT TAT |
N/A |
| Days Test Performed |
Monday -Friday |
| Performed by BHS |
None |
| See Availability |
|
| Reference Lab |
LabCorp of America |
| Reference Lab Code |
007864 Disopyramide, Serum or Plasma |
| Clinical Use |
Evaluate toxicity; monitor therapeutic levels Disopyramide shares electrophysiologic properties with quinidine and procainamide. Up to 80% of oral dose is absorbed. Half-life is 4 to 10 hours. Eighty percent of the drug is excreted in the urine. Dosage must be modified (dosage intervals prolonged) in patients with renal failure. Serious toxic effects are depression of myocardial contractility and disturbances in myocardial conduction. Other effects include dry mouth, constipation, urinary hesitancy, and blurred vision. Metabolite N-desisopropyl disopyramide is also pharmacologically active. Concomitant treatment with phenytoin may lead to decreased serum levels of disopyramide. There may be cumulative effect with other Class I antiarrhythmic drugs (lidocaine, procainamide). |
| Reference Range |
|
| Critical Value |
|
|
Component |
|
|
Reference Range |
|
|
Critical Value |
|
 |
|
| Testing Sample Type |
Serum or Plasma |
| Min Lab Testing Volume |
1.0 mL |
| Special Handling |
Collection:Transfer separated serum or plasma to a plastic transport tube. |
| Lab Notes |
|
| Methodology |
IA - Immunoassay |
| Limitations |
Causes for Rejection: Gel-barrier tube; hemolysis; lipemia; icteric specimen
|
